Recently Added |view more
Presented by Fox Chase Cancer Center and the Temple Health Office for Continuing Medical Education, these enduring materials are designed to help clinicians translate the data from key presentations from the 2021 San Antonio Breast Cancer ...
Two studies are testing whether the stroma can be used to the patient’s advantage.
Until late 2021, patients with recurrent cervical cancer had limited options for treatment. Available treatments included standard chemotherapy regimens and the VEGF-inhibitor bevacizumab.
According to a new study from researchers at Fox Chase, mRNA vaccine for COVID-19 is just as safe for people with cancer as it is for cancer-free individuals.
Highlights of the 2021 Division of General Surgery
Amoroso is part of the nurse-led dedicated intravesical clinic that helps optimize treatment for patients and workflow for other physicians and nurses.
Researchers at Fox Chase Cancer Center have developed a model that predicts disease recurrence and survival in patients with intermediate- and high-risk localized kidney cancer more accurately than existing prognostic models.
Fox Chase Cancer Center is renowned for its use of the latest treatment methods for a range of liver and related cancers.
Fox Chase’s Alexander Kutikov, MD, FACS, is leading an international effort to create a centralized, streamlined, point-of-care resource for the management of adrenal masses.
An American Society of Clinical Oncology (ASCO) collaborative report named the use of molecular profiling the top advance of 2021, but also identified priority areas for future research.
Hereditary cancer syndromes cause a significant portion of gynecologic malignancies. Many times, gynecologic cancers are diagnosed in the late stages, at a time when treatment options are limited.
Watch this short video on the three components of breast cancer screening—brought to you by Andrea Porpiglia, MD, MSc, FACS, Assistant Professor, Department of Surgical Oncology at Fox Chase.
The phase-1 trial will test a new targeted therapy called seclidemstat in patients with relapsed or refractory Ewing sarcoma or Ewing-related Sarcomas.
A partnership between the Fox Chase solid tumor oncologists and their colleagues in bone marrow transplantation tests the potential of adoptive cell therapies for the treatment of solid tumors.